Eventually those totals you see on the screencap above hit 219 -- 212, followed by a second vote, 220 -- 211, to adopt the tweaks to the Senate bill that were necessary to get the 219 on the first vote.
A couple Obama signatures later and the US has the comprehensive health care reform legislation that has dominated the agenda for months. And now for the hard part: selling the reform bill and coming out the other end politically alive.
Check out our family of pubs-- especially "The Pink Sheet" and The RPM Report -- for various takes on the consequences of the House vote and the implications for industry. Pharma, with its 32 million new customers, is a big winner (as we've been saying all along).
While you were staying up late to watch C-SPAN ...
- The NY Times recaps Sunday's drama.
- And Bloomberg looks at the impact on drug companies.
- As for the stock market, Reuters reports that at least in Europe, investors aren't fazed by the passage of HCR.
- Meanwhile, Roche aims to extend the label for its Mabthera juggernaut in Europe.
- Finally, some basketball news. You know at one point getting comprehensive health care reform passed seemed less likely than Cornell reaching the Sweet 16 of the NCAA Mens Basketball Tourney. Next up for the Big Red, a looming upset of 1 seed Kentucky up in Syracuse.
image from flicker user paulbettner used under a creative commons license.